Bevacizumab combined with chemotherapy for ovarian cancer A protocol for systematic review and meta-analysis

Background: The impact of bevacizumab (an anti-vascular endothelial growth factor therapy) remains uncertain, which has been the focus of studies on the management of ovarian cancer (OC). We performed a protocol for systematic review and meta-analysis to assess the efficacy and safety of bevacizumab combined with chemotherapy in OC. Methods: The presentation of methods and results in this systematic review was performed according to the evaluation guidelines for health care interventions provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol. This study will use the Cochrane Library, Web of Science, PubMed, Embase, Allied and Complementary Medicine Database, China Biomedical Literature Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Database, and Ongoing Clinical Trials Database. The risk of bias of included studies is estimated by taking into consideration the characteristics including random sequence generation, allocation concealment, blinding of patients, blinding of outcome assessment, completeness of outcome data, selective reporting, and other bias by Cochrane Collaboration's tool. All analyses were performed with Review Manager (RevMan) software, version 5.3. Results: The results of this systematic review and meta-analysis will be published in a peer-reviewed journal. Conclusion: Bevacizumab combined with chemotherapy may improve progression-free survival and overall survival in patients with OC.

Automated summary

This study aims to evaluate the efficacy and safety of bevacizumab combined with chemotherapy in ovarian cancer patients. The results will be analyzed through systematic review and meta-analysis, and published in a peer-reviewed journal.